Do GLP-1 Patches Actually Work?

No. No transdermal, topical or patch formulation of any GLP-1 medication has FDA approval, and the reason is physical rather than regulatory: the molecules are roughly eight to ten times too large to cross intact skin. This page explains the size problem, what the FDA actually found inside a product sold as a GLP-1 patch, and what legitimate therapy looks like instead.

The size problem

Skin is a barrier before it is anything else, and it is a selective one. The widely cited threshold for passive absorption through intact skin is the 500 Dalton rule, set out by Bos and Meinardi in Experimental Dermatology in 2000. Their argument rested on three observations: nearly all contact allergens are under 500 Daltons, all commonly used topical dermatological drugs are under 500 Daltons, and every known transdermal drug is under 500 Daltons.

Now the two molecules in question, taken from the DESCRIPTION section of their FDA labels:

These are peptides with 187 and 225 carbon atoms respectively. They are not small molecules that need a clever delivery vehicle. They are an order of magnitude outside the range of anything that has ever been successfully delivered through skin.

What the FDA found inside one

In March 2026 the FDA issued a warning letter to a seller marketing an "SMGT-GLT-1 Nano Microneedle Patch" on eBay for type 2 diabetes, weight loss and cardiovascular protection. The agency stated that no approved application under section 505 of the Federal Food, Drug, and Cosmetic Act was in effect for the product.

The detail worth sitting with is what the seller's own marketing said the patch contained: "a blend of fat-burning ingredients (such as caffeine, green tea extract, or other thermogenic compounds)."

A product named and sold as a GLP-1 patch, by its own description, contained caffeine and green tea extract. Not semaglutide. Not tirzepatide. That is one documented product rather than the whole category, but it is what an FDA enforcement record actually shows.

What the FTC says about anything worn on skin

The Federal Trade Commission publishes a reference guide listing seven weight-loss claims it says cannot be true, for use by media vetting advertisements. The seventh is:

Causes substantial weight loss by wearing a product on the body or rubbing it into the skin.

Their stated reasoning is that weight loss is an internal metabolic process, and nothing worn or applied to skin can drive it substantially. That guidance covers supplements, over-the-counter products, patches, creams and wraps. It does not apply to prescription drugs, which is exactly the right scope here.

The nuance most articles get wrong

It would be easy to end this with "GLP-1s have to be injected." That is no longer true, and the truth is more interesting.

As of 2026, an oral semaglutide tablet is FDA-approved for chronic weight management, taken daily rather than injected weekly. So the molecule can be delivered without a needle.

But look at what that took. The tablet is co-formulated with an absorption enhancer, absorption happens predominantly in the stomach, and the resulting oral bioavailability is roughly 1 to 2% — against 89% for the subcutaneous injection. The industry needed dedicated absorption-enhancer technology and had to accept losing about 98% of the dose to get this molecule across the lining of the gut, which is far more permeable than skin.

No equivalent approved technology exists for intact skin. A patch that claims to do casually what an entire formulation science program barely achieved through a more permeable membrane is making a very large claim.

One more distinction, because it is the easiest thing to get wrong: Rybelsus is also oral semaglutide, but it is approved for type 2 diabetes glycemic control, not for weight loss. The oral semaglutide approved for weight management is a different application at a different strength. They are not interchangeable.

What legitimate therapy looks like

Every FDA-approved GLP-1 product is either a subcutaneous injection or an oral tablet. That holds across semaglutide, tirzepatide, liraglutide, dulaglutide and exenatide. There is no approved patch, no approved cream, no approved transdermal anything.

It is also worth separating two different risks. Patches are the one discussed above. The other is compounded and counterfeit product bought online: the FDA has warned about counterfeit Ozempic reaching the U.S. supply chain, about labels naming compounding pharmacies that do not exist, and in March 2026 warned 30 telehealth companies over how they marketed compounded GLP-1s. Those warnings are about injectables and orals, not patches, but they point the same direction — the sourcing matters as much as the molecule.

Revive offers semaglutide and tirzepatide injections under medical supervision, with the prescription, the titration plan and the follow-up that go with them. Whether either is appropriate for you is a decision for your prescribing clinician.

Angelica Alcaraz, BSN, RN, will assess your specific needs during your consultation.

Book a Free Consultation